NHO Revive Announces Expanded Access Protocol for Daraxonrasib
NHO Revive will offer pre-approval access to Daraxonrasib for eligible stage 4 pancreatic cancer patients through an Expanded Access Protocol. NEBRASKA, NE, UNITED STATES, July 22, 2026 /EINPresswire.com/ -- NHO Revive is pleased to announce …